Corvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a report released on Monday. The brokerage issued a sell rating on the stock. Separately, Mizuho reaffirmed a neutral rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research report on Thursday, March 30th. Corvus Pharmaceuticals Price […]

Related Keywords

,Corvus Pharmaceuticals Company Profile ,Corvus Pharmaceuticals Price Performance ,News Ratings For Corvus Pharmaceuticals Daily ,Corvus Pharmaceuticals Inc ,Acadian Asset Management ,Morgan Stanley ,Bailard Inc ,Corvus Pharmaceuticals ,Get Rating ,Street Corp ,Asset Management ,Two Sigma Investments ,Sigma Investments ,Adenosine Production Inhibitor ,Corvus Pharmaceuticals Daily ,Nasdaq Crvs ,Ccrvs ,Medical ,Initiated Coverage ,Stocknews Com ,